William Blair starts Argenx with Outperform on ‘best-in-class’ product

William Blair analyst Myles Minter last night initiated coverage of Argenx with an Outperform rating and $460.66 fair value estimate. Argenx is a leading commercial-stage biopharma company developing novel therapies for rare autoimmune disorder, Minter tells investors in a research note. The analyst believes Vyvgart is a "best-in-class product with a first-mover advantage over peers." He "conservatively" estimates $2.8B in peak sales for the generalized myasthenia gravis indication alone.